Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   JOURNAL OF OPHTHALMIC AND VISION RESEARCH   JANUARY 2011 , Volume 6 , Number 1; Page(s) 18 To 25.
 
Paper: 

DELAYED CORNEAL EPITHELIAL HEALING AFTER INTRAVITREAL BEVACIZUMAB: A CLINICAL AND EXPERIMENTAL STUDY

 
 
Author(s):  COLOMBRES GUSTAVO A., GRAMAJO ANA L., ARRAMBIDE MARIA P., JUAREZ SILVINA M., AREVALO J FERNANDO, BAR JORGE, JUAREZ CLAUDIO P., LUNA J.D.*
 
* CENTRO PRIVADO DE OJOS ROMAGOSA-FUNDACION VER, CORDOBA, ARGENTINA
 
Abstract: 

Purpose: To report corneal epithelial defects (CEDs) and delayed epithelial healing after intravitreal bevacizumab (IVB) injection and to describe delayed corneal epithelial healing with topical administration of bevacizumab in an experimental rabbit model.
Methods: A retrospective chart review was performed on 850 eyes of 850 patients with neovascular eye disease and diabetic macular edema who had received 1.25 to 2.5 mg IVB. In the experimental arm of the study, photorefractive keratectomy was used to create a 3 mm CED in the right eyes of 18 New Zealand rabbits which were then randomized to three equal groups. All rabbits received topical antibiotics, additionally those in group A received topical bevacizumab and animals in group B were treated with topical corticosteroids. The rate of epithelial healing was assessed at different time points using slitlamp photography.
Results: In the clinical study, seven eyes of seven subjects developed CEDs the day after IVB injection. All of these eyes had preexisting corneal edema. The healing period ranged from 3 to 38 days (average 11 days) despite appropriate medical management. In the experimental study, topical bevacizumab and corticosteroids both significantly hindered corneal epithelial healing at 12 and 24 hours.
Conclusion: Bevacizumab was demonstrated to cause CEDs in clinical settings.
Moreover, corneal epithelial healing was delayed by topical application of bevacizumab, in the experimental model. These short-term results suggest that corneal edema may be considered as a risk factor for epithelial defects after IVB.

 
Keyword(s): INTRAVITREAL BEVACIZUMAB, CORNEAL EPITHELIAL DEFECT, CORNEAL EDEMA, ANTIANGIOGENICS, COMPLICATIONS
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

COLOMBRES, G., & GRAMAJO, A., & ARRAMBIDE, M., & JUAREZ, S., & AREVALO, J., & BAR, J., & JUAREZ, C., & LUNA, J. (2011). DELAYED CORNEAL EPITHELIAL HEALING AFTER INTRAVITREAL BEVACIZUMAB: A CLINICAL AND EXPERIMENTAL STUDY. JOURNAL OF OPHTHALMIC AND VISION RESEARCH, 6(1), 18-25. https://www.sid.ir/en/journal/ViewPaper.aspx?id=191271



Vancouver: Copy

COLOMBRES GUSTAVO A., GRAMAJO ANA L., ARRAMBIDE MARIA P., JUAREZ SILVINA M., AREVALO J FERNANDO, BAR JORGE, JUAREZ CLAUDIO P., LUNA J.D.. DELAYED CORNEAL EPITHELIAL HEALING AFTER INTRAVITREAL BEVACIZUMAB: A CLINICAL AND EXPERIMENTAL STUDY. JOURNAL OF OPHTHALMIC AND VISION RESEARCH. 2011 [cited 2021June22];6(1):18-25. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=191271



IEEE: Copy

COLOMBRES, G., GRAMAJO, A., ARRAMBIDE, M., JUAREZ, S., AREVALO, J., BAR, J., JUAREZ, C., LUNA, J., 2011. DELAYED CORNEAL EPITHELIAL HEALING AFTER INTRAVITREAL BEVACIZUMAB: A CLINICAL AND EXPERIMENTAL STUDY. JOURNAL OF OPHTHALMIC AND VISION RESEARCH, [online] 6(1), pp.18-25. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=191271.



 
  pdf-File
Yearly Visit 36
 
 
Latest on Blog
Enter SID Blog